Creative Bioarray provides convenient analysis services for transcript analysis in the development of therapeutic methods and drug targets in immuno-oncology. We have accumulated a lot of experience in the field of mRNA and ncRNA in-situ analysis, which can help customers design analysis plans from sample processing. Choose existing commercial probe products or design customized probes for customers for analysis and testing. Our team has complete equipment and a professional team to establish a one-stop service process.

Immuno-oncology and Therapeutic Target Development

Immuno-oncology is a new treatment strategy, which is different from traditional treatments that directly target tumors or destroy the blood supply of tumors. It aims to enhance the patient's immune response to tumor cells. The immune system seems to play a dual role in cancer: it can not only inhibit tumor growth by destroying cancer cells or inhibiting their outgrowth, but it can also promote tumor progression by selecting tumor cells that are more suitable for survival. Understanding how the immune system affects the development and progression of cancer has always been the most concerned issue in immunology. Immunotherapy is becoming the main method of cancer treatment, and its focus is on the development of inhibitors or costimulators of cell mediators that induce immunosuppression (immune checkpoints) to enhance anti-tumor immune responses. The immune system recognizes tumor-associated antigens (so-called neoantigens) and eliminates tumor cells that express them. The expression of these neoantigens (neoepitopes) is considered to be the result of new mutations (such as DNA damage). Visual analysis can be used to confirm the spatial expression pattern of new epitopes in tumor tissues and help the development of drugs and therapeutic targets.

A wide range of anti-tumor immune cells are known to support the clearance of tumor cells.Fig 1. A wide range of anti-tumor immune cells are known to support the clearance of tumor cells. (Dempke W C M, et al. 2017)

Transcript In Situ Analysis in Immuno-oncology

We provide complete in situ visualization solutions for the analysis of tissue expression patterns of targets in immuno-oncology research. Different immunological methods for immune checkpoint pathways have shown promise in the development, which requires analysis of the expression of related signal pathways and targets. Our in-situ analysis solution can be used to discover preclinical and clinical evidence, providing new ideas for studying anti-tumor immune responses. The development of other therapies such as cancer vaccines and chimeric antigen receptor T cell (CAR-T) therapies requires a better understanding of the function of immune cells in the tumor microenvironment and their interaction with different cell types (signaling pathways). At present, probe products and technologies that can be used to detect co-expression profiles (checkpoints, cell-specific markers, etc.) of any target mRNA in in-situ analysis techniques have been developed. The application of highly specific probe products improves the accuracy of in situ analysis. Our solution can not only be used for co-expression profiling of transcripts of interest, but also provide optional protein level analysis services.

Transcript co-expression analysis strategy in immuno-oncology.Fig 2. Transcript co-expression analysis strategy in immuno-oncology.

If you are interested in our FISH service, please contact us for cooperation. We look forward to cooperating with you in the near future.


  1. Dempke W C M, Fenchel K, Uciechowski P, et al. Second-and third-generation drugs for immuno-oncology treatment—the more the better?[J]. European journal of cancer, 2017, 74: 55-72.
All products and services on this website are only suitable for non-medical purposes.



Online Inquiry

Inquiry Basket ( 0 ) Choose Dye*